RCAG
SGMO

Rehmann Capital Advisory Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Rehmann Capital Advisory Group’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-3
Closed -$34 – 2137
2018
Q4 		$34 Sell
3
-70
-96% -$870 ﹤0.01% 1822
2018
Q3 		$1.24K Hold
73
– – ﹤0.01% 1938
2018
Q2 		$1.04K Hold
73
– – ﹤0.01% 1961
2018
Q1 		$1K Buy
+73
New +$1.56K ﹤0.01% 1923

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Rehmann Capital Advisory Group's SGMO Position: Q1 2019 in Review

Rehmann Capital Advisory Group sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2019, closing a stake of 3 shares — an estimated $34 sold.

Rehmann Capital Advisory Group first reported a position in SGMO in Q1 2018 and held it in 4 quarters. The position peaked at $1.24K in Q3 2018. 187 funds tracked by Wall St. Rank hold SGMO as of Q1 2019.

  • Rehmann Capital Advisory Group reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2019 after selling out during the quarter.
  • Rehmann Capital Advisory Group sold 3 SANGAMO THERAPEUTICS INC shares in Q1 2019, an estimated $34.
  • Rehmann Capital Advisory Group first reported a position in SANGAMO THERAPEUTICS INC in Q1 2018 and held it in 4 quarters.
  • Rehmann Capital Advisory Group's SANGAMO THERAPEUTICS INC position peaked at $1.24K in Q3 2018.
  • 187 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q1 2019, filed 22 May 2019.